Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ9tetrahydrocannabinol

British Journal of Pharmacology

Volumn 170, Issue 7, 2013, Pages 1365-1373

  Wright Jr , M Jerry ^a   Vandewater, Sophia A ^a   Taffe, Michael A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

cannabis; Macaca mulatta; marijuana; working memory

Indexed keywords

CANNABIDIOL; DRONABINOL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; ASSOCIATIVE MEMORY; COGNITIVE DEFECT; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG EFFECT; MALE; MENTAL TASK; MONKEY MODEL; MOTOR PERFORMANCE; NONHUMAN; PAIRED ASSOCIATE LEARNING; PRIORITY JOURNAL; SELF ORDERED SPATIAL SEARCH MEMORY TASK; SENSORIMOTOR FUNCTION; TASK PERFORMANCE; VISUOSPATIAL ASSOCIATIVE MEMORY DEFICIT; VISUOSPATIAL PAIRED ASSOCIATES LEARNING TASK; ANIMAL; ANIMAL MODEL; CHEMICALLY INDUCED; COGNITION; DRUG EFFECTS; HEMISPHERIC DOMINANCE; MEMORY; MEMORY DISORDERS; MOLECULAR GENETICS; MOTIVATION; MOTOR ACTIVITY; PSYCHOLOGY; RHESUS MONKEY; TIME; TOXICITY;

ANIMALS; BEHAVIOR, ANIMAL; CANNABIDIOL; COGNITION; DRONABINOL; FUNCTIONAL LATERALITY; MACACA MULATTA; MALE; MEMORY; MEMORY DISORDERS; MODELS, ANIMAL; MOLECULAR SEQUENCE DATA; MOTIVATION; MOTOR ACTIVITY; TIME FACTORS;

EID: 84887802398     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12199     Document Type: Article

References (52)

1. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O′Carroll C, et al. (2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 66: 442-451.
2. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35: 764-774.
3. Brady KT, Balster RL, (1980). The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys. Psychopharmacology (Berl) 72: 21-26.
4. Braff DL, Silverton L, Saccuzzo DP, Janowsky DS, (1981). Impaired speed of visual information processing in marijuana intoxication. Am J Psychiatry 138: 613-617.
5. Browning PG, Gaffan D, (2008). Impairment in object-in-place scene learning after uncinate fascicle section in macaque monkeys. Behav Neurosci 122: 477-482.
6. Burgdorf JR, Kilmer B, Pacula RL, (2011). Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend 117: 59-61.
7. Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS, (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 367: 3364-3378.
8. Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gebhart GF, Gonder JC, et al. (1996). Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, National Research Council: Washington, DC.
9. Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. (2012). Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184: 1143-1150.
10. Crean RD, Vandewater SA, Katner SN, Huitron-Resendiz S, Taffe MA, (2011). Chronic alcohol consumption impairs visuo-spatial associative memory in periadolescent rhesus monkeys. Drug Alcohol Depend 114: 31-40.
11. De Petrocellis L, Di Marzo V, (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 5: 103-121.
12. Eggan SM, Lewis DA, (2007). Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 17: 175-191.
13. Fant RV, Heishman SJ, Bunker EB, Pickworth WB, (1998). Acute and residual effects of marijuana in humans. Pharmacol Biochem Behav 60: 777-784.
14. Gomes FV, Reis DG, Alves FH, Correa FM, Guimaraes FS, Resstel LB, (2012). Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol 26: 104-113.
15. Heishman SJ, Stitzer ML, Yingling JE, (1989). Effects of tetrahydrocannabinol content on marijuana smoking behavior, subjective reports, and performance. Pharmacol Biochem Behav 34: 173-179.
16. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H, (2005). Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 16: 487-496.
17. Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J, (2007). Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res 97: 109-117.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: The ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
19. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, et al. (2011). Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) 218: 443-457.
20. Kurzthaler I, Hummer M, Miller C, Sperner-Unterweger B, Gunther V, Wechdorn H, et al. (1999). Effect of cannabis use on cognitive functions and driving ability. J Clin Psychiatry 60: 395-399.
21. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM, (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol 159: 950-957.
23. Malkova L, Mishkin M, (2003). One-trial memory for object-place associations after separate lesions of hippocampus and posterior parahippocampal region in the monkey. J Neurosci 23: 1956-1965.
24. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci U S A 109: E2657-E2664.
25. Morgan CJ, Schafer G, Freeman TP, Curran HV, (2010). Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 197: 285-290.
26. Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, et al. (2011). Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 29: 1-10.
27. Oreja-Guevara C, (2012). Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Review of Neurotherapeutics 12 (4 Suppl.): 3-8.
28. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
29. Resstel LB, Tavares RF, Lisboa SF, Joca SR, Correa FM, Guimaraes FS, (2009). 5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats. Br J Pharmacol 156: 181-188.
30. Robson P, (2011). Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10: 675-685.
31. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM, (2008). Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol 18: 569-577.
32. de Rover M, Pironti VA, McCabe JA, Acosta-Cabronero J, Arana FS, Morein-Zamir S, et al. (2011). Hippocampal dysfunction in patients with mild cognitive impairment: a functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia 49: 2060-2070.
33. RTI-International (2012). Data Sheet: Marijuana Cigarettes Vol. 12792-0109-120, pp 1-2: RTI International.
34. Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, et al. (2011). A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Hum Psychopharmacol 26: 224-236.
35. Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P, (2011). Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential. Neurosci Lett 496: 60-64.
36. Stern CA, Gazarini L, Takahashi RN, Guimaraes FS, Bertoglio LJ, (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 37: 2132-2142.
37. Taffe MA, (2004). Effects of parametric feeding manipulations on behavioral performance in macaques. Physiol Behav 81: 59-70.
38. Taffe MA, (2012a). Delta9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience 201: 125-133.
39. Taffe MA, (2012b). Delta(9)Tetrahydrocannabinol impairs visuo-spatial associative learning and spatial working memory in rhesus macaques. J Psychopharmacol 26: 1299-1306.
40. Taffe MA, Weed MR, Gold LH, (1999). Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8: 203-212.
41. Taffe MA, Davis SD, Gutierrez T, Gold LH, (2002a). Ketamine impairs multiple cognitive domains in rhesus monkeys. Drug Alcohol Depend 68: 175-187.
42. Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH, (2002b). Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psychopharmacology (Berl) 160: 253-262.
43. Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH, (2004). Modeling a task that is sensitive to dementia of the Alzheimer's type: individual differences in acquisition of a visuo-spatial paired-associate learning task in rhesus monkeys. Behav Brain Res 149: 123-133.
44. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, et al. (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94: 191-198.
45. Von Huben SN, Davis SA, Lay CC, Katner SN, Crean RD, Taffe MA, (2006). Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys. Psychopharmacology (Berl) 188: 586-596.
46. Wade DT, Makela P, Robson P, House H, Bateman C, (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10: 434-441.
47. Weed MR, Taffe MA, Polis I, Roberts AC, Robbins TW, Koob GF, et al. (1999). Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. Brain Res Cogn Brain Res 8: 185-201.
48. Wilson WH, Ellinwood EH, Mathew RJ, Johnson K, (1994). Effects of marijuana on performance of a computerized cognitive- neuromotor test battery. Psychiatry Res 51: 115-125.
49. Winsauer PJ, Lambert P, Moerschbaecher JM, (1999). Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol 10: 497-511.
50. Wright MJ, Jr, Vandewater SA, Angrish D, Dickerson TJ, Taffe MA, (2012). Mephedrone (4-methylmethcathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques. Br J Pharmacol 167: 1342-1352.
51. Zuardi AW, Teixeira NA, Karniol IC, (1984). Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269: 12-19.
52. Zuardi AW, Hallak JE, Crippa JA, (2012). Interaction between cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology (Berl) 219: 247-249.